Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33
- Polygenes, risk prediction, and targeted prevention of breast cancer.N Engl J Med. 2008; 358: 2796-2803
- Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.JAMA. 2016; 315: 68-76
- Homologous Retinoblastoma in Identical Twins.Trans Am Ophthalmol Soc. 1929; 27: 173-176
- Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?.Ann Intern Med. 1969; 71: 747-752
- Carcinoma of the breast and ovary in three families.Surg Gynecol Obstet. 1971; 133: 644-648
- Heredity and multiple primary malignant neoplasms: six cancer families.Am J Med Sci. 1967; 254: 322-329
- Linkage of early-onset familial breast cancer to chromosome 17q21.Science. 1990; 250: 1684-1689
- Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families.Proc Natl Acad Sci U S A. 1988; 85: 3044-3048
- A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.Science. 1994; 266: 66-71
- Identification of the breast cancer susceptibility gene BRCA2.Nature. 1995; 378: 789-792
- Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.JAMA Oncol. 2015; 1: 23-32
- Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.Clin Cancer Res. 2006; 12: 3209-3215
- A review on age-related cancer risks in PTEN hamartoma tumor syndrome.Clin Genet. 2021; 99: 219-225
- Breast and other cancers in families with ataxia-telangiectasia.N Engl J Med. 1987; 316: 1289-1294
- Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.Science. 1999; 286: 2528-2531
- Low-penetrance susceptibility to breast cancer due to CHEK2(∗)1100delC in noncarriers of BRCA1 or BRCA2 mutations.Nat Genet. 2002; 31: 55-59
- Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.Lancet. 2001; 358: 1389-1399
- Family history and the risk of breast cancer: a systematic review and meta-analysis.Int J Cancer. 1997; 71: 800-809
- Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.N Engl J Med. 2021; 384: 428-439
- A Population-Based Study of Genes Previously Implicated in Breast Cancer.N Engl J Med. 2021; 384: 440-451
- A global reference for human genetic variation.Nature. 2015; 526: 68-74
- Genome-wide association studies.Nat Rev Methods Primers. 2021; 1: 59
- Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future.Cancer Epidemiol Biomarkers Prev. 2018; 27: 380-394
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.Am J Hum Genet. 2019; 104: 21-34
- The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.Genet Med. 2021; 23: 1726-1737
- Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.J Natl Cancer Inst. 2017; 109
- Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.J Clin Oncol. 2021; 39: 2564-2573
- Porcelain-fused-to-metal crowns as replacements for denture teeth in removable partial denture construction.J Prosthet Dent. 1987; 58: 53-56
- Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.Genet Med. 2020; 22: 1653-1666
- Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.J Natl Cancer Inst. 2021; 113: 329-337
- CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants.Cancer Epidemiol Biomarkers Prev. 2021; 30: 469-473
- Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model.JCO Precis Oncol. 2021; : 5
- Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.JCO Precis Oncol. 2021; : 5
- Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.Int J Epidemiol. 2022; 50: 1897-1911
- BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.Genet Med. 2019; 21: 1708-1718
- Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.Nat Med. 2021; 27: 1876-1884
- Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.Am J Hum Genet. 1995; 56: 265-271
- Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.Am J Hum Genet. 1997; 61: 120-128
- Bilateral prophylactic mastectomy: issues and concerns.J Natl Cancer Inst Monogr. 1995; : 37-42
- Prophylactic oophorectomy in inherited breast/ovarian cancer families.J Natl Cancer Inst Monogr. 1995; : 33-35
- First do no harm" also applies to cancer susceptibility testing.Cancer J Sci Am. 1996; 2: 250-252
- BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.JAMA. 1996; 275: 1885-1892
- Cancer genetic susceptibility testing: ethical and policy implications for future research and clinical practice. Cancer Genetic Studies Consortium, National Institutes of Health.J Law Med Ethics. 1997; 25 (230): 243-251
- Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent.JAMA. 1997; 277: 1467-1474
- Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.JAMA. 1993; 269: 1970-1974
- Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition.Am J Hum Genet. 1994; 55: i-iv
- Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests.Ann Intern Med. 2003; 138: 571-575
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.JAMA. 2017; 317: 2402-2416
- Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample.J Clin Oncol. 2002; 20: 514-520
- Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations.Ann Oncol. 2011; 22: i44-i49
- Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.N Engl J Med. 2002; 346: 1616-1622
- Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.J Clin Oncol. 2004; 22: 1055-1062
- Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.Br J Cancer. 2012; 107: 24-30
- Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.N Engl J Med. 2001; 345: 159-164
- Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.Clin Cancer Res. 2016; 22: 3971-3981
- Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.N Engl J Med. 2002; 346: 1609-1615
- Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.J Natl Cancer Inst. 2001; 93: 1633-1637
- Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.J Clin Oncol. 2014; 32: 2224-2230
- Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2019; 322: 652-665
- Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.Ann Intern Med. 2005; 143: 355-361
- Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.Int J Cancer. 2015; 136: 668-677
- Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.Breast Cancer Res Treat. 2013; 140: 135-142
- ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.Pract Radiat Oncol. 2020; 10: 235-242
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med. 2018; 24: 628-637
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.N Engl J Med. 2017; 377: 523-533
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.N Engl J Med. 2018; 379: 753-763
- Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.Eur J Cancer. 2021; 152: 68-77
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med. 2021; 384: 2394-2405
- Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.Ann Surg Oncol. 2019; 26: 3025-3031
- Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.J Med Genet. 2022; 59: 220-229
- It was an important part of my treATMent": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing.Hered Cancer Clin Pract. 2022; 20: 6
- Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.Fam Cancer. 2022; 17: 1-7
- Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.Genet Med. 2021; 23: 2105-2113
- Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer.Fam Cancer. 2022; 21: 295-304
- The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review.Cancers (Basel). 2022; 14
- Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.J Clin Oncol. 2020; 38: 1398-1408
- A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.JAMA Oncol. 2019; 5: 1718-1730https://doi.org/10.1001/jamaoncol.2019.3323
- BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.ESMO Open. 2018; 3: e000328
- Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?.J Clin Oncol. 2019; 37: 453-460
- Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.J Clin Oncol. 2020; 38: 1409-1418
- Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.J Clin Oncol. 2021; 39: 3430-3440
- Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.Cancer. 2021; 127: 828-833
- Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.J Clin Oncol. 2020; 38: 2080-2106
- Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.J Clin Oncol. 2021; 39: 2528-2534
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
